当前位置: X-MOL 学术HPB › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A systematic review of small for size syndrome after major hepatectomy and liver transplantation.
HPB ( IF 2.9 ) Pub Date : 2019-11-27 , DOI: 10.1016/j.hpb.2019.10.2445
Georgina E Riddiough 1 , Christopher Christophi 1 , Robert M Jones 1 , Vijayaragavan Muralidharan 1 , Marcos V Perini 1
Affiliation  

BACKGROUND Major hepatectomy (MH) and particular types of liver transplantation (LT) (reduced size graft, living-donor and split-liver transplantation) lead to a reduction in liver mass. As the portal venous return remains the same it results in a reciprocal and proportionate rise in portal venous pressure potentially resulting in small for size syndrome (SFSS). The aim of this study was to review the incidence, diagnosis and management of SFSS amongst recipients of LT and MH. METHODS A systematic review was performed in accordance with the 2010 Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. The following terms were used to search PubMed, Embase and Cochrane Library in July 2019: ("major hepatectomy" or "liver resection" or "liver transplantation") AND ("small for size syndrome" or "post hepatectomy liver failure"). The primary outcome was a diagnosis of SFSS. RESULTS Twenty-four articles met the inclusion criteria and could be included in this review. In total 2728 patients were included of whom 316 (12%) patients met criteria for SFSS or post hepatectomy liver failure (PHLF). Of these, 31 (10%) fulfilled criteria for PHLF following MH. 8 of these patients developed intractable ascites alongside elevated portal venous pressure following MH indicative of SFSS. CONCLUSION SFSS is under-recognised following major hepatectomy and should be considered as an underlying cause of PHLF. Surgical and pharmacological therapies are available to reduce portal congestion and reverse SFSS.

中文翻译:

大型肝切除术和肝移植术后小体积综合征的系统评价。

背景主要肝切除术(MH)和特定类型的肝移植(LT)(缩小尺寸的移植物、活体供体和分裂肝移植)导致肝脏质量的减少。由于门静脉回流保持不变,它导致门静脉压力相互成比例地升高,可能导致小体积综合征 (SFSS)。本研究的目的是回顾 LT 和 MH 受者中 SFSS 的发生率、诊断和管理。方法 根据 2010 年系统评价和 Meta 分析首选报告项目 (PRISMA) 指南进行系统评价。2019 年 7 月使用以下术语搜索 PubMed、Embase 和 Cochrane 图书馆:(“主要肝切除术”或“肝切除术”或“肝移植”)和(“ 结果 24 篇文章符合纳入标准,可纳入本综述。共纳入 2728 名患者,其中 316 名 (12%) 患者符合 SFSS 或肝切除术后肝功能衰竭 (PHLF) 的标准。其中,31 人(10%)符合 MH 后 PHLF 的标准。其中 8 名患者在 MH 指示 SFSS 后出现顽固性腹水并伴有门静脉压升高。结论 SFSS 在主要肝切除术后未被充分认识,应被视为 PHLF 的潜在原因。手术和药物疗法可用于减少门静脉充血和逆转 SFSS。结果 24 篇文章符合纳入标准,可纳入本综述。共纳入 2728 名患者,其中 316 名 (12%) 患者符合 SFSS 或肝切除术后肝功能衰竭 (PHLF) 的标准。其中,31 人(10%)符合 MH 后 PHLF 的标准。其中 8 名患者在 MH 指示 SFSS 后出现顽固性腹水并伴有门静脉压升高。结论 SFSS 在主要肝切除术后未被充分认识,应被视为 PHLF 的潜在原因。手术和药物疗法可用于减少门静脉充血和逆转 SFSS。31 (10%) 名符合 MH 后 PHLF 的标准。其中 8 名患者在 MH 指示 SFSS 后出现顽固性腹水并伴有门静脉压升高。结论 SFSS 在主要肝切除术后未被充分认识,应被视为 PHLF 的潜在原因。手术和药物疗法可用于减少门静脉充血和逆转 SFSS。31 (10%) 名符合 MH 后 PHLF 的标准。其中 8 名患者在 MH 指示 SFSS 后出现顽固性腹水并伴有门静脉压升高。结论 SFSS 在主要肝切除术后未被充分认识,应被视为 PHLF 的潜在原因。手术和药物疗法可用于减少门静脉充血和逆转 SFSS。
更新日期:2019-11-27
down
wechat
bug